| TIC1 Protein | |
|---|---|
| Current Wiki Label | TIC1 (provisional mitochondrial iron-import context page) |
| Closest Human Axis | Mitoferrin pathway (SLC25A37 / SLC25A28) |
| Core Biology | Mitochondrial iron uptake, heme and Fe-S cluster biogenesis |
| Primary Relevance | Oxidative stress, ferroptosis pressure, mitochondrial vulnerability |
| Related Mechanisms | [Iron metabolism](/mechanisms/iron-metabolism), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) |
This page tracks the mitochondrial iron-import mechanism under the current TIC1 label used in parts of NeuroWiki. In mammals, the best-established mitochondrial iron importers are mitoferrin proteins (SLC25A37 and SLC25A28), while yeast ortholog systems include Mrs3/Mrs4.[1][2][3] The mechanistic importance for neurodegeneration is high: mitochondrial iron excess or miscompartmentalization can drive reactive oxygen species generation, respiratory-chain impairment, and ferroptosis-prone states.[4][5]
Because "TIC1" nomenclature can be ambiguous across databases/species, claims on this page are intentionally anchored to well-supported mitochondrial iron import biology rather than to a single unresolved symbol mapping. The disease-relevant mechanism is still actionable and should be cross-linked to iron metabolism, ferroptosis, and mitochondrial dysfunction.
Mitochondria require iron for two central outputs:
Both outputs are essential for respiratory-chain enzymes and multiple metabolic proteins.[2:1][3:1][6]
Evidence from yeast and mammalian systems supports a conserved concept: dedicated inner-membrane carriers move iron into the mitochondrial matrix where scaffold proteins and assembly systems partition iron into heme and Fe-S pathways.[1:1][2:2][6:1]
Insufficient import impairs energy metabolism and Fe-S biology, while excess import promotes redox-active iron accumulation and oxidative injury. Neurodegenerative risk often emerges from this imbalance, not simply from "high" or "low" iron alone.[4:1][5:1]
Substantia nigra pars compacta shows reproducible iron dyshomeostasis in Parkinson disease, and mitochondrial vulnerability in dopaminergic neurons amplifies injury from redox-active iron pools.[7][8] Iron-dependent oxidative stress can reinforce alpha-synuclein misfolding and mitochondrial failure loops.
Alzheimer brains show region-specific iron accumulation and disturbed iron-handling signatures. Mitochondrial iron stress can exacerbate lipid peroxidation, proteostasis burden, and synaptic failure.[5:2][9]
Friedreich ataxia provides a high-confidence disease model linking defective mitochondrial iron handling to Fe-S biogenesis failure, respiratory dysfunction, and selective neuronal/cardiac vulnerability.[10]
Ferroptosis is a regulated cell-death state driven by iron-dependent lipid peroxidation. Mitochondrial iron flux and buffering status can modify ferroptotic sensitivity in stressed neural systems.[4:2][11]
Brain-penetrant iron modulators (for example deferiprone) have been tested in neurodegeneration to lower pathological redox-active pools, though efficacy and safety depend strongly on disease stage and target tissue.[12]
Future strategy classes include:
Overcorrection can worsen Fe-S and heme insufficiency. Therapeutic design must preserve essential mitochondrial iron use while reducing toxic iron chemistry.
When this page is cited elsewhere, use wording such as:
That language is more evidence-faithful than asserting a fully resolved human single-gene TIC1 driver.
Mühlenhoff U, Stadler JA, Richhardt N, et al. A specific role of the yeast mitochondrial carriers Mrs3/4p in mitochondrial iron acquisition under iron-limiting conditions. Journal of Biological Chemistry. 2003. ↩︎ ↩︎
Shaw GC, Cope JJ, Li L, et al. Mitoferrin is essential for erythroid iron assimilation. Nature. 2006. ↩︎ ↩︎ ↩︎
Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J. Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Molecular and Cellular Biology. 2009. ↩︎ ↩︎
Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017. ↩︎ ↩︎ ↩︎
Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. Journal of Neurochemistry. 2016. ↩︎ ↩︎ ↩︎
Rouault TA. Mitochondrial iron overload: causes and consequences. Current Opinion in Genetics & Development. 2016. ↩︎ ↩︎
Dexter DT, Wells FR, Lee AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. Journal of Neurochemistry. 1989. ↩︎
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology. 2014. ↩︎
Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with MRI. Journal of Alzheimer's Disease. 2013. ↩︎
Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich's ataxia. Journal of Neurochemistry. 2013. ↩︎
Do Van B, Gouel F, Jonneaux A, et al. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiology of Disease. 2016. ↩︎
Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxidants & Redox Signaling. 2014. ↩︎